TY - JOUR PY - 2020// TI - Comparison of driving capacity among patients with amyotrophic lateral sclerosis and healthy controls using the lane change task JO - Journal of the neurological sciences A1 - Hayes, Heather Anne A1 - Hu, Nan A1 - Wang, Xuechen A1 - Gibson, Summer A1 - Mathy, Pamela A1 - Berggren, Kiera A1 - Bromberg, Mark SP - 116741 EP - 116741 VL - 413 IS - N2 - OBJECTIVE: Compare driving capacity of individuals with Amyotrophic Lateral Sclerosis (ALS) and healthy controls (HC) using a driving simulation program.

METHODS: A prospective study was performed on individuals with ALS who reported they were still driving, and a group of HCs. Demographic data included age and gender. Assessment included cognitive assessments (Montreal cognitive assessment [MoCA] and ALS Cognitive Behavioral Scale [ALS-CBS]); gait speed (m/s); ALS Functional Rating Scale-revised total score (ALSFRS-R); and simulated driving assessment (Lane Change Task [LCT]). The LCT is a simple assessment tool which simulates the visual, cognitive, and motor demands of driving to detect at-risk drivers and uses distractions (secondary tasks) to quantify the performance loss on the primary task (lane changes).

RESULTS: Twenty-eight individuals with ALS (22 males, mean age 64 years) and 20 HCs (7 males, mean age 59 years) were studied. Individuals with mild to moderate ALS (ALSFRS-R mean 36.2) were older, had mild cognitive difficulty (MoCA 24 vs 27; ALS-CBS 14.19 [SD 3.85]) and mobility decline (gait speed 1.1 vs 1.4 m/s) compared to HC. Driving assessment using the LCT found no differences in baseline scores or during motor, cognitive, or visually distracting conditions.

CONCLUSIONS: Individuals with ALS with mild to moderate disease progression, with cognitive and motor weakness still demonstrate similar driving capacity to HCs using a driving simulation task. Driving assessment needs to be expanded longitudinally and perhaps with more robust measures to more precisely identify types of driving challenges that lead to cessation of driving in individuals with ALS.

Copyright © 2020 Elsevier B.V. All rights reserved.

Language: en

LA - en SN - 0022-510X UR - http://dx.doi.org/10.1016/j.jns.2020.116741 ID - ref1 ER -